Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,942 shares of the biotechnology company’s stock after buying an additional 166 shares during the period. New York Life Investment Management LLC’s holdings in Sarepta Therapeutics were worth $959,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Mizuho Markets Americas LLC acquired a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $29,813,000. Westfield Capital Management Co. LP grew its holdings in Sarepta Therapeutics by 40.1% during the 3rd quarter. Westfield Capital Management Co. LP now owns 806,400 shares of the biotechnology company’s stock worth $97,752,000 after acquiring an additional 230,618 shares in the last quarter. TD Asset Management Inc increased its position in shares of Sarepta Therapeutics by 377.7% in the 3rd quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock worth $24,805,000 after purchasing an additional 161,788 shares during the last quarter. Avidity Partners Management LP grew its stake in Sarepta Therapeutics by 51.3% in the third quarter. Avidity Partners Management LP now owns 450,000 shares of the biotechnology company’s stock worth $54,549,000 after purchasing an additional 152,500 shares in the last quarter. Finally, abrdn plc bought a new stake in Sarepta Therapeutics in the fourth quarter valued at about $14,159,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on SRPT shares. Royal Bank of Canada lifted their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Evercore ISI boosted their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research note on Tuesday, February 20th. Wedbush restated an “outperform” rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, JPMorgan Chase & Co. decreased their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $160.60.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,815,030. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,815,030. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,731 shares of company stock valued at $3,248,319. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Up 0.7 %

SRPT stock opened at $136.04 on Wednesday. The firm’s 50-day moving average is $125.47 and its two-hundred day moving average is $111.07. The company has a market capitalization of $12.86 billion, a price-to-earnings ratio of 1,236.73 and a beta of 0.95. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $159.89. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.44) earnings per share. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 2.23 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.